Venus Remedies Ltd

Venus Remedies Ltd share price ticked higher by 4.22% to Rs 1455.25 after the company's net profit rose by 11.67% to Rs 25.65 crore, while revenue from operations gained significantly 22.31% to Rs 218.76 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.54 lakh crore, rising 3.38%. It has inched up 0.07% over last one week and edged lower by 3.01% in last one month while the market capitalization of Venus Remedies Ltd has eased by 8.59% and 9.54% in the same period respectively. Profit before tax (PBT) of Venus Remedies Ltd stood at Rs 33.47 crore in Q3 FY26, rallying 26.35% year-on-year, and climbing 11.42% quarter-on-quarter. EBITDA came in at Rs 42 crore, jumping 43.56% YoY and surging by 33.01% sequentially. Total expenses soared by 22.69% to Rs 185.8 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 97.39 crore, increasing 17.14% YoY, while employee benefits expense was at Rs 26.53 crore, surging 13.52% YoY. For the TTM ended FY26, revenue from operations improved 17.88% to Rs 769.6 crore, while net profit saw a strong growth of 126.81% to Rs 102.79 crore, compared to previous TTM. EBITDA jumped by 5474% to Rs 134.7 crore, and PBT jumped 86.80% to Rs 134.16 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 155.77 crore in FY26, as against Rs 86.45 crore in FY25. Venus Remedies Ltd surged by 232.86% in last one year, significantly outperforming the benchmark BSE Sensex which has declined by 13.18% during the same period.

Net profit of Venus Remedies rose 139.27% to Rs 22.97 crore in the quarter ended June 2026 as against Rs 9.60 crore during the previous quarter ended June 2025. Sales rose 30.38% to Rs 178.86 crore in the quarter ended June 2026 as against Rs 137.18 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales178.86137.18 30 OPM %19.1211.21 - PBDT36.8118.78 96 PBT30.0412.60 138 NP22.979.60 139 Powered by Capital Market - Live

Venus Remedies will hold a meeting of the Board of Directors of the Company on 20 July 2026.

Venus Remedies announced that the 37th Annual General Meeting(AGM) of the company will be held on 20 August 2026.

Venus Remedies announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 10 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Net profit of Venus Remedies rose 126.19% to Rs 47.50 crore in the quarter ended March 2026 as against Rs 21.00 crore during the previous quarter ended March 2025. Sales rose 33.05% to Rs 259.40 crore in the quarter ended March 2026 as against Rs 194.97 crore during the previous quarter ended March 2025. For the full year,net profit rose 126.81% to Rs 102.79 crore in the year ended March 2026 as against Rs 45.32 crore during the previous year ended March 2025. Sales rose 17.88% to Rs 769.60 crore in the year ended March 2026 as against Rs 652.89 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales259.40194.97 33 769.60652.89 18 OPM %24.4514.87 -19.1410.50 - PBDT68.3635.75 91 159.8284.42 89 PBT61.6131.04 98 134.1661.91 117 NP47.5021.00 126 102.7945.32 127 Powered by Capital Market - Live

Net profit of Venus Remedies rose 193.78% to Rs 43.45 crore in the quarter ended March 2026 as against Rs 14.79 crore during the previous quarter ended March 2025. Sales rose 31.65% to Rs 259.01 crore in the quarter ended March 2026 as against Rs 196.74 crore during the previous quarter ended March 2025. For the full year,net profit rose 88.98% to Rs 99.31 crore in the year ended March 2026 as against Rs 52.55 crore during the previous year ended March 2025. Sales rose 19.28% to Rs 768.73 crore in the year ended March 2026 as against Rs 644.47 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales259.01196.74 32 768.73644.47 19 OPM %22.9512.83 -18.7211.64 - PBDT64.0829.33 118 155.3790.77 71 PBT57.5724.84 132 130.6869.15 89 NP43.4514.79 194 99.3152.55 89 Powered by Capital Market - Live

Venus Remedies has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company's move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with diifferentiated therapies in regulated markets. Plerixafor is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into peripheral blood for collection and autologous transplantation. It is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant.

Venus Remedies will hold a meeting of the Board of Directors of the Company on 26 May 2026.

Net profit of Venus Remedies rose 30.51% to Rs 25.58 crore in the quarter ended December 2025 as against Rs 19.60 crore during the previous quarter ended December 2024. Sales rose 2.12% to Rs 180.26 crore in the quarter ended December 2025 as against Rs 176.52 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales180.26176.52 2 OPM %20.8110.21 - PBDT40.0320.38 96 PBT33.4714.97 124 NP25.5819.60 31 Powered by Capital Market - Live